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Predictors Of Long Term Outcome In Heart Failure Patients With Very Low
Left Ventricular Ejection Fraction And Severe Mitral Regurgitation After
Percutaneous Edge To Edge Mitral Valve Repair
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Background: Data is limited on the long-term outcome of patients with a left ven-
tricular ejection fraction (LV-EF) 25% and severe mitral regurgitation (MR) after
percutaneous edge-to-edge mitral valve repair.
Methods: From 2009 to 2012, 34 patients with a LV-EF 25% and severe MR were
intended to treat with percutaneous edge-to-edge mitral valve repair in the two uni-
versity hospitals of Munich.
Results: Long-term follow-up (up to 4.5 years) revealed a high 1-year mortality of
50% and the putative existence of two subgroups, one with a poor short-term and a
second one with a favourable long-term outcome. In an univariate Cox proportional
hazard model, NYHA functional class IV (hazard ratio [HR] 4.1, p¼0.009), cardio-
genic shock (HR 8.6, p¼0.015), lack of hypertension (HR 3.9, p¼0.013), low
tricuspid annular plane systolic excursion (TAPSE < 14mm)(HR 4.0, p¼0.035),
severely impaired RV-function (HR 3.3, p¼0.014), elevated right ventricular tricuspid
pressure gradient (RVTG  30mmHg)(p¼0.0016), dialysis (HR 6.6, p¼0.001),
EuroSCORE II (HR 1.3, p¼0.008) and STS risk score (HR 1.4, p¼0.004) were
signiﬁcantly associated with 1-year mortality. Dialysis was an independent predictor
of 1-year mortality.
Conclusions: Percutaneous edge-to-edge mitral valve repair possibly leads to a
favourable long-term outcome in a subgroup of patients with a LV-EF 25% and
severe MR. Predictors like NYHA functional class, cardiogenic shock, TAPSE, RV-
function, RVTG, the need for dialysis, EuroSCORE II and STS risk score might be
used to consider percutaneous edge-to-edge mitral valve repair primarily for patients
with favourable prognosis.TCT-800
Improvement in Quality of Life in Patients With Degenerative Mitral
Regurgitation at Prohibitive Surgical Risk Following Transcatheter
Mitral Valve Repair with the MitraClip System
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Background: We sought to evaluate the improvement in quality of life (QOL) in
patients with severe degenerative mitral regurgitation (DMR) at prohibitive surgical
risk undergoing transcatheter mitral valve repair with the MitraClip.
Methods: MitraClip repair was performed in 21 prohibitive risk DMR patients with
4+ MR after a multi-disciplinary heart team deemed them to be ineligible for surgery.
The Kansas City Cardiomyopathy Questionnaire (KCCQ) was administered at base-
line and one-month follow-up to assess QOL.
Results:Mean age was 789 years, and mean STS score was 12.2%. Twenty patients
(95.3%) had successful deployment of the MitraClip device. There were no proceduralB234 JACC Vol 64/11/Suppl B j September 13–17, 2014 j Tdeaths. At 30-day follow-up there were two deaths (9.5%), 1 due to respiratory failure
at 48 hours and 1 due to a stroke at 3 weeks. At 1-month follow-up, 17 patients
(81.0%) had grade 1-2+ MR. QOL as assessed by the KCCQ in 18 patients was
signiﬁcantly improved (P< 0.001) in 1-month survivors (Figure). Eight different
quality domains were used for assessment of QOL. These included activity (p¼0.002),
edema (p¼0.001), fatigue (0.001), shortness of breath (p¼0.001), orthopnea
(p¼0.003), enjoyment of life (p-0.001), satisfaction at status quo health (p¼0.001) and
activity limitation (p¼0.01). There was a signiﬁcant improvement in all domains
assessed.Conclusions: Transcatheter mitral valve repair with the MitraClip in prohibitive
surgical risk patients with DMR results in substantial improvement in QOL. Further
studies are needed to examine whether these results are durable and associated with
other improved clinical outcomes.Valvular disease - Mitral: Transcatheter therapies
(non-MitraClip)
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Safety, Feasibility And Efﬁcacy Of Transapical Off-Pump Mitral Valve Repair
With Neochord Implantation
Andrea Colli1, Erica Manzan1, Fabio Zucchetta1, Cristiano Sarais1,
Demetrio Pittarello2, Gino Gerosa1
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Background: Transapical off-pump mitral valve repair with Neochord implantation
(TOP-MINI) is a recently introduced minimally invasive technique to treat degener-
ative mitral valve prolapse or ﬂail. We sought to assess the safety, feasibility and
efﬁcacy of the TOP-MINI procedure.
Methods: From November 2013 to April 2014, 25 patients with severe symptomatic
degenerative mitral regurgitation (MR) with leaﬂet prolapse or ﬂail were treated.
Acute procedure success was deﬁned as postoperative residual MR less than moderate
(MR< 2+). At 1 and 3 months follow-up, we evaluated clinical conditions and
residual MR grade with transthoracic echocardiography.
Results: Median age was 76 years (range 31-90 years), median Euroscore-I was
5.98% (range 0.88-38.9%) and median STS score was 1.73% (range 0.22-14.6%).
Twenty one patients (84%) presented a posterior mitral leaﬂet prolapse, 3 (12%) an
anterior leaﬂet prolapse and 1 (4%) a combined anterior-posterior prolapse. The
procedure was successfully completed in all patients with correct chordae implantation
achieving a signiﬁcant MR reduction. A median of 4 Gore-Tex Neochords (range 3-6)
were implanted for each patient: 8 patients (32%) received 3 chordae, 12 (48%)
received 4 chordae, 4 (16%) had 5 chordae and 1 (4%) had 6 chordae. Median pro-
cedural time was 135 min (range 90-200 min). No death, stroke, acute myocardial
infarction or bleeding events occurred within 30-days. At 1 month and 3 months
follow-up 22 patients (88%) were in good clinical conditions (NYHA I or II) with
residual MR < 2+. Ten patients (40%) presented no MR, 6 (24%) mild MR (1+) andCT Abstracts/Valvular disease - Mitral: Transcatheter therapies (non-MitraClip)
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM6 (24%) moderate MR (2+). Only 3 patients (12%) presented MR>3+ and were
successfully re-operated. Two patients underwent conventional mitral valve replace-
ment, while the latter underwent Neochord re-implantation.
Conclusions: Our initial results with the TOP-MINI procedure showed that this
minimal invasive technique is safe, feasibble and provide signiﬁcant clinical beneﬁt.
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Background: Reoperation for aortic and mitral valve bioprosthetic deterioration is
associated with signiﬁcant morbidity and mortality. Transcatheter valve-in-valve
(ViV) implantation is now utilized as an alternative in the high-risk patient. However,
little is known about the long-term follow-up of Melody (Medtronic, Minneapolis,
MN) ViV for systemic bioprosthesis failure.
Methods: Between February 2012 and February 2013, 12 patients (7414years,
66% male, STS mitral:aortic 14.314%:13.510%) presented to our institution with
severe bioprosthetic mitral (25 to 33mm, n¼9) and aortic (23 to 25mm, n¼3)
dysfunction at a median of 3426 days [IQR:2669 to 3318] following surgery. Etiology
of mitral and aortic dysfunction was severe regurgitation in 67% // 0%, stenosis
in 11% // 67%, and combined in 22% // 33%. All individuals had transthoracic
echocardiography performed preoperatively and at 1mo, 6mo, and annually thereafter.
Percutaneous transseptal/transapical approach with an arteriovenous rail was utilized
for mitral ViV and retrograde transaortic for aortic ViV.
Results: Complete percutaneous mitral and aortic ViV was successfully performed in
all patients, with 3 patients having two Melody valves implanted in the mitral position.
The mean NYHA functional class improved from 3.40.5 to 2.01.1 (p¼< 0.05)
over a median follow of 485 days and a maximum follow-up of 818 days (IQR:259 to
578). The mean transvalvular gradient improved from 10.33.4 to 3.62.2 (p< 0.05)
for mitral and from 40.220 to 9.57.8 (p< 0.05) for aortic ViV implantation, with
all patients having mild or no residual regurgitation.
Conclusions: In high-risk patients, Melody ViV implantation for left-sided valvular
heart disease is a promising therapeutic option in individuals with degenerated bio-
prostheses. Early results suggest that it is associated with favorable outcomes however
long term durability needs to be further assessed.
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Background: The NeoChord DS1000 system is used deliver artiﬁcial chordae ten-
dineae (neochordae), under beating-heart conditions with transesophageal echocardi-
ography (TEE) used to guide the device to the target leaﬂet for deployment of the
neochordae. The aim of the study is to identify reﬁnements in intraoperative imaging
technology that directly inﬂuence accuracy and reproducibility of the key steps of
neochordae implantation using NeoChord DS1000 system: intra-cardiac navigation,
crossing of mitral valve plane, mitral leaﬂet capture, assessment of neochordae
efﬁcacy.
Methods: At Vilnius University Hospital Santariskiu Klinikos 42 Patients have un-
dergone the NeoChord operation since June 2012. In the ﬁrst 13 cases, intraoperative
guidance was achieved by 2D echocardiography only, while in the remaining cases a
combination of 2D and 3D echocardiographic guidance was utilized. Currently, 2D
imaging is utilized ﬁrst to introduce and navigate the NeoChord instrument inside the
LV until the mitral valve plane is crossed. Imaging is then switched to 3D and leaﬂet
capture and chorda deployment are performed. Tension is then applied to the artiﬁcial
chorda and its effectiveness in reducing prolapse is evaluated.
Results: In the 42 patients, an average of 4 chordae per patient were implanted (Range
2-7). In the 2D+3D group, as compared to the 2D-only group, average number of
chordae implanted per patient was increased by 44% (3.9 vs 2.7, P< 0.05), average
time to implant a single chorda was decreased by 18% (4.4 vs 5.5 minutes, P¼NS);
number of total deployment attempts per case was decreased by 27% (5.8 attempts vs
8.2, P< 0.05). Furthermore, intraoperative 3D visualization of the mitral valve anat-
omy allowed a better planning of the operation and precise targeting of speciﬁc
portions of the prolapsing leaﬂets
Conclusions: 3D real-time echocardiography provides signiﬁcant beneﬁts over
2D-only, and has become an indispensable intraprocedural guidance tool.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/ValvulTCT-804
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Background: Transcatheter mitral valve-in-valve / valve-in-ring implantation is an
emerging therapeutic alternative for patients with failed mitral valves after surgical
intervention and may obviate the need for a redo operation. We aimed to evaluate the
clinical results of this technique using a large worldwide registry.
Methods: The registry included 190 patients with degenerated mitral valves
after surgical intervention (17.4% ring only, median of 9 years post procedure). Mean
age 73.6  12.6 years; 65.2% female (STS score 14.4  11.9%). The mode of
failure was regurgitation (n¼70, 37%), stenosis (n¼47, 25%), and combined
(n¼73, 38%).
Results: Transcatheter Edwards SAPIEN (Edwards Lifesciences, Irvine, CA) im-
plantation was performed in 93.7% of cases (23 mm in 11.1%, 26 mm in 57.4%, and
29 mm in 25.3%) and Inovare in 6.3%. Procedural access was transapical in 161 cases
(84.7%); transseptal in 23 (12.1%), and through the left atrium via right mini-thora-
cotomy in 6 (3.2%). Twenty-three combined procedures (12.1%) included aortic
valve-in-valves, aortic valve replacement, tricuspid valve-in-ring implantation, and
paravalvular leak closure. Device malposition appeared in 5.3% of cases and post
implantation valvuloplasty was utilized in 8%. Post-procedure, mitral valve area was
2.1  0.7 cm2 and valve mean gradients was 6.2  2.7mmHg. Signiﬁcant mitral
regurgitation (+2) was observed in 4.2% of patients. Median length of hospital stay
was 8 days. At 30-day follow-up, all-cause mortality was 8.9%, 2.2% of patients had
stroke and 85.8% were at New York Heart Association functional class I/II. 1-year
mortality was 22.3%. Independent predictors for 1-year mortality included baseline
STS score (HR 1.04, CI 1.02-1.06) and renal failure (GFR< 60cc/min, HR 2.37,
CI 1.06-5.28).
Conclusions: Mitral valve-in-valve/ valve-in-ring implantations, performed in
extremely high-risk patients, were clinically effective in most patients with degener-
ative mitral valves after surgery. However, safety and efﬁcacy concerns include device
malposition and elevated post procedural gradients.
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Background: Percutaneous mitral balloon valvuloplasty (PMV) is the treatment of
choice for patients with symptomatic mitral stenosis (MS). Rapid improvement in
symptoms and hemodynamic parameters can be observed after increasing mitral valve
area and decreasing left atrial pressure. However, left atrial pressure has been shown
to be inﬂuenced by both MS severity and left atrial compliance (Ca). Effects of PMV
on Ca are still unknown. The aim of this study is to deﬁne the immediate effects of
PMV on Ca and to identify factors inﬂuencing the changes in Ca post PMV in patients
with MS.
Methods: We enrolled patients in our institution with MS who underwent successful
PMV from December 2012 to May 2014. Transthoracic echocardiography (TTE) was
performed in all the patients pre and 24-h post procedure. PMV was performed by the
Inoue technique, guided by TTE. Gas analyzes of blood samples from aorta and
pulmonary artery were obtained and pressure tracings were recorded from aorta, left
ventricle and left atrium before and after the balloon dilation in order to calculate
cardiac index and the left atrial compliances.
Results: Sixty-one patients were enrolled. The mean age was 4512 years,
84% were female. Mean mitral valve area (MVA) pre procedure was 0.96  0.25
cm2. After PMV we observed a signiﬁcant decrease in mPAP (35.112.4 mmHg
vs. 29.69.7 mmHg, p< 0.001) and an increase in cardiac output (4.11.3 L/min
vs. 4.41.3 L/min, p< 0.001). The median Ca pre procedure was 6.6 [4.5-9.2]
mL/mmHg with increase after PMV to 12.4 [6.6-22.5] mL/mmHg (p< 0.001).
The change in Ca correlated with changes in mitral transvalvular gradient, pul-
monary artery pressure, left atrial pressure and pulmonary vascular resistance
pre and post-PMV. Multivariate analysis revealed that the degree of change post
PMV in mPAP (p¼0.004), left atrial pressure (p¼0.012) and pulmonary
vascular resistance index (p¼0.001) were independently associated with changes
in Ca.
Conclusions: This study demonstrates that successful PMV can signiﬁcantly increase
Ca, which is associated with improvement in cardiac hemodynamics. These results
may also provide potential mechanistic insights into the pathophysiology of the he-
modynamic changes seen in MS.ar disease - Mitral: Transcatheter therapies (non-MitraClip) B235
